Home
Welcure Drugs & Pharmaceuticals Ltd EPS

Welcure Drugs & Pharmaceuticals Ltd
NSE: WELCUREDRUGS
EPS
Key Highlights
- The Earning per Share of Welcure Drugs & Pharmaceuticals Ltd is ₹ 0.17 as of 21 Feb 25 .
- The earning per share of Welcure Drugs & Pharmaceuticals Ltd changed from ₹ -0.02 to ₹ 0.04 over 7 quarters. This represents a CAGR of NaN% .
Historical Earning per Share of Welcure Drugs & Pharmaceuticals Ltd
EPS, or Earnings Per Share, is a financial metric that represents the portion of a company's profit allocated to each outstanding share of common stock. It indicates a company's profitability and is calculated by dividing net income by the number of outstanding shares.
Historical Earning per Share of Welcure Drugs & Pharmaceuticals Ltd
Company Fundamentals for Welcure Drugs & Pharmaceuticals Ltd
Market Cap
81 Cr
EPS
0.2
P/E Ratio (TTM)
42.8
P/B Ratio (TTM)
0.8
Day’s High
7.89
Day’s Low
7.19
DTE
0.0
ROE
1.4
52 Week High
15.81
52 Week Low
3.76
ROCE
1.4
Market Price of Welcure Drugs & Pharmaceuticals Ltd
1M
1Y
3Y
5Y
Last Ten Days Market Price
Date | |
---|---|
21 Feb 2025 | 7.28 |
20 Feb 2025 | 7.56 |
19 Feb 2025 | 7.95 |
18 Feb 2025 | 8.36 |
17 Feb 2025 | 8.8 |
14 Feb 2025 | 9.26 |
13 Feb 2025 | 9.25 |
12 Feb 2025 | 9.61 |
11 Feb 2025 | 10.08 |
10 Feb 2025 | 10.31 |
SWOT Analysis Of Welcure Drugs & Pharmaceuticals Ltd
BlinkX Score for Welcure Drugs & Pharmaceuticals Ltd
Asset Value vs Market Value of Welcure Drugs & Pharmaceuticals Ltd
Market Value
₹ 82
Asset Value
Value addition
2729.3 X
₹ 0
* All values are in ₹ crores
Competitive Comparison of EPS
Company | Market Cap | EPS |
---|
Welcure Drugs & Pharmaceuticals Ltd | 81.91 | 0.17 |
Sun Pharmaceuticals Industries Ltd | 394223 | 49.16 |
Divis Laboratories Ltd | 152610 | 77.86 |
Cipla Ltd | 119067 | 61.78 |
Torrent Pharmaceuticals Ltd | 102739 | 55.02 |
Dr Reddys Laboratories Ltd | 96124 | 64.37 |
Company | |
---|---|
Welcure Drugs & Pharmaceuticals Ltd | 81.91 |
Sun Pharmaceuticals Industries Ltd | 394223 |
Divis Laboratories Ltd | 152610 |
Cipla Ltd | 119067 |
Torrent Pharmaceuticals Ltd | 102739 |
Dr Reddys Laboratories Ltd | 96124 |
Historical Market Cap of Welcure Drugs & Pharmaceuticals Ltd
Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore
Historical Market Cap of Welcure Drugs & Pharmaceuticals Ltd
Historical Revenue of Welcure Drugs & Pharmaceuticals Ltd
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services.\r\r\n\r\r\nTypes of Revenue:\r\r\n\r\r\n1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered.\r\r\n\r\r\n2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees.\r\r\n\r\r\nFormula for Revenue:\r\r\n\r\r\nThe formula for calculating revenue is based on two goods & services:\r\r\n\r\r\nFor goods:\r\r\nRevenue = Avg unit price x Number of Units sold\r\r\n\r\r\nFor services:\r\r\nRevenue = Avg unit price x Number of Customers served.
Historical Revenue of Welcure Drugs & Pharmaceuticals Ltd
Historical EBITDA of Welcure Drugs & Pharmaceuticals Ltd
PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.
Historical EBITDA of Welcure Drugs & Pharmaceuticals Ltd
Historical Net Profit of Welcure Drugs & Pharmaceuticals Ltd
Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions.\r\r\n\r\r\nNet Profit formula is expressed as:\r\r\n\r\r\nNet Profit = Total Revenue - Total Expense\r\r\n\r\r\nNet Profit Margin Ratio:\r\r\n\r\r\nNet Profit Margin Ratio = Net Profit / Total Revenue
Historical Net Profit of Welcure Drugs & Pharmaceuticals Ltd
Dividend Payout Over Time
Welcure Drugs & Pharmaceuticals Ltd News Hub
Welcure Drugs & Pharmaceuticals reports standalone net loss of Rs 0.35 crore in the June 2024 quarter
Net Loss of Welcure Drugs & Pharmaceuticals reported to Rs 0.35 crore in the quarter ended June 2024
Read more
14 Aug 24
Welcure Drugs & Pharmaceuticals to table results
Welcure Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 A
Read more
09 Aug 24
Welcure Drugs & Pharmaceuticals to hold board meeting
Welcure Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 2 Se
Read more
30 Aug 24
Welcure Drugs & Pharmaceuticals to conduct AGM
Welcure Drugs & Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will
Read more
11 Sept 24